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Epilepsy is a common neurological disorder in the pediatric
population, affecting up to one percent of children.1,2 Nowadays
there are many pharmacological choices for treatment of pediatric
epilepsy. However, despite the frequent use of antiepileptic drugs
(AEDs), remarkably little is known about the safety and efficacy
of most of these medications in pediatric epilepsy population.
Many types of endocrine and metabolic abnormalities are associ-
ated with epilepsy and its medications.3,4 AEDs may be associated
with either increases or reductions in body weight.5 Epilepsy and
AEDs may alter weight homeostasis regulating process including
the two important homeostatic hormones; leptin and insulin.6
Ghrelin regulates the secretion of leptin and insulin.7 Ghrelin is a
gastric hormone, known to initiate food intake; prolonged treat-
ment with ghrelin causes increased body weight.8
Levetiracetam (LEV) is a second-generation anticonvulsant drug
that has been evaluated in the pediatric population, gaining FDA
approval in 2004 for adjunctive therapy in children from 4 years
of age with partial onset seizures, and most recently, in 2012, as
adjunctive therapy for partial onset seizures in infants and children
one month of age and older with epilepsy. Some studies demon-
strate its effectiveness as a monotherapy in partial epilepsy.9–11
Recently Weijenberg and his colleagues systematically searched
the literature using Web of Science, PubMed and Embase up to
August 2014 for articles on levetiracetammonotherapy in children,
and they found that the evidence for levetiracetammonotherapy in
children is minimal however; its efficacy and tolerability seemed
to be good and comparable to other AEDs.12
Data regarding the impact of LEV on body weight were adapted
mainly from studies done on adult epileptic.13–17To the best of our knowledge, there are no previous reports that
examined the effect of LEV monotherapy on body weight in pedi-
atric epilepsy population. Therefore, the aim of the present study
is (1) to prospectively investigate the changes in body weight,
BMI, and body composition using bioelectrical impedance analysis
(BIA) technique,18 and (2) to evaluate serum ghrelin level and insu-
lin resistance after 6 months of LEV monotherapy in children with
idiopathic focal epilepsy to test their contribution in weight
changes.
Methods
Participants
This is a prospective comparative case-control study that was
conducted from April 2013 to June 2015. Patients’ ages ranged
between 6 and 10 years. They were recruited consecutively during
their initial presentation at Neurology Outpatient Clinic (OPC),
Mansoura University Children Hospital (MUCH), Mansoura, Egypt.
The study population was restricted to those with newly diagnosed
idiopathic focal epilepsy.
Epilepsy was defined according to the guidelines of the Interna-
tional League against Epilepsy.19 Electroencephalogram (EEG) and
MRI were done to all patients at presentation to exclude secondary
causes of epilepsy. Exclusion criteria included: (1) Children who
previously received any AEDs or medications known to affect
growth (e.g., steroids). (2) History of an overt medical disorder
before the onset of epilepsy that affect the process of growth, phys-
ical development, and body composition (e.g., thyroid disorders,
hepatic, renal, muscle or bone diseases). (3) Patients with physical
or neurological impairments prevented normal physical activity. In
addition, 22 healthy controls recruited from the general outpatient
clinic at MUCH matched for age, sex, and socioeconomic status
were also included in this study. The periodic estimation of dietary
habit and physical activity were done at the beginning and at the
end of the study. The dietary habits including the characteristics
of meals and snacks were checked by a general questionnaire.
The physical activity was evaluated by the duration and frequency
of specific exercises and daily activities.
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obtained from parents of included patients and controls. The pro-
tocol of the study was approved by the Institutional Research
Board (IRB) of Mansoura Faculty of Medicine.
Procedures
All patients and healthy controls underwent the same research
protocol, which included medical, neurological, and endocrinolog-
ical histories and examinations. Pubertal staging was evaluated
according to the Tanner method.20,21
Data collection included age, sex, and seizure related variables
including; age at onset, duration of illness, frequency of seizures,
and degree of patients’ control. Patients with focal seizure were
selected consecutively at their first presentation in Neurology
OPC. All patients were assigned to LEV monotherapy with start
doses of 15 mg/kg/day with increment of 5 mg/kg/day till they
achieve complete clinical control of fits (mean dosage of 30 mg/
kg/day) and were followed up monthly over 6-months period.
The drug dosage was individually adjusted to obtain appropriate
balance between seizure control and tolerability. They were sub-
jected to detailed clinical examination and laboratory evaluation
before LEV monotherapy (month 0) and the 6th months of therapy.
Seizure frequency and adverse effects were documented with a
mother-recorded seizure diary when the patient visited the outpa-
tient clinic. Patients were considered controlled if they remained
seizure free for the entire study period.
Anthropometric measures
Anthropometric data were collected including; standing height
to the nearest 0.1 cm in bare feet using portable Harpender sta-
diometer and weight to the nearest 0.1 kg using digital weight
scale, the measurements were repeated twice and the average
was recorded. Body mass index (BMI) was calculated as weight
in kilograms divided by the square of the height in meters.22
Height, weight, and BMI were expressed as Z-scores using pub-
lished age- and sex-specific reference data of these parameters in
healthy Egyptian children.23
Waist circumference (WC; cm) is measured using a tape at mid-
point between lateral iliac crest and lowest rib margin at the end of
normal expiration where hip circumference (HC; cm) is measured
at the level of greater trochanter and symphysis pubis. Waist to
Hip ratio (WHR) is used as a marker of central adiposity.
Body composition assessment
Whole-body and segmental body composition were determined
using a bioelectrical impedance analysis (BIA) technique, using
body composition analyzer ‘‘Tanita BC-418 MA” (Tanita Corp.,
Tokyo, Japan). Measurements were obtained on the morning after
an overnight fast, after being requested to void their bladder. The
subject stood on the two foot plates with legs apart catching the
two hand electrodes for one minute. The BIA data include, body
fat mass (kg), body fat free mass (FFM) (kg) both for total body,
and segmental analysis (legs, arms and trunk).
Laboratory investigations
Fasting blood samples were taken between 8 and 10 am to
avoid bias due to diurnal variations. All whole blood samples
(3 ml) were centrifuged to obtain serum and then immediately fro-
zen at 20 C within 1 h after sampling, and stored until the anal-
ysis was carried out. Serum fasting blood glucose (FBG) was
measured by end point colorimetric reagents supplied by SPIN-
REACT (S.A./S.A.U Ctra. Santa Coloma, 7 E-17176 SANT ESTEVEDE BAS (GI) SPAIN). Insulin was measured using enzyme- linked
immune sorbent assay (ELISA) kit supplied by Cal Bio Tech (1046
Austin Dr, Spring Vally, CA 91978, USA). Serum ghrelin levels were
measured by the enzyme-linked immune sorbent assay (ELISA) kit
supplied by Ray Bio tech, Inc. (3607 Parkway Lane, Suite 200 Nor-
cross, GA 30092, USA) and were expressed as ng/ml.
Insulin resistance index (IRI) was calculated according to home-
ostasis model assessment insulin resistance (HOMA-IRI), through
Matthews et al. 24 formula where IR is considered at values
P2.5. [HOMA-IR = fasting blood glucose (mg/dl)  fasting insulin
(lUI/ml)/405.]Statistical analysis
All data analysis was performed using a statistical package for
social science program (SPSS) version 17. Non parametric data
were expressed in median and range (minimum–maximum).
Parametric data were expressed in Mean ± Standard deviation. Fre-
quency (Number-%) used to represent categorical variables (sex).
Inter-group comparison of categorical data was done by using chi
square test (X2-value). Student’s t-test (Unpaired) was used to
compare between the mean of numerical data (parametric) of
two groups, while Student’s t-test (Paired) was used to compare
between the mean of numerical (parametric) data of two related
groups. Mann–Whitney U test was used to compare between
numerical (non-parametric) data of two different groups. While
Wilcoxon signed rank test was used to compare between the mean
of numerical (non-parametric) data of two related groups. Spear-
man correlation coefficient test was used for correlating different
parameters. A p value <0.05 was considered statistically significant
in all analyses.Results
Initially, the study included 26 pre-pubertal Egyptian children
with newly diagnosed idiopathic focal epilepsy of whom 20
patients (76.9%) completed the study protocol. This was not possi-
ble for the other six patients because five patients were excluded
due to treatment failure, and one patient was lost the follow up.
The duration of epilepsy (between appearance of symptoms and
initiation of LEV treatment) ranged between 1 and 2 months.
A. Baseline clinical and laboratory characteristics of control and
patients groups:
There was no difference between patient and control groups at
baseline as regards age and sex. In addition, no significant differ-
ences were detected between the two groups as regards anthropo-
metric measurements (Table 1 and Fig. 1). Moreover, no significant
differences were observed between the two groups as regards body
composition parameters (Table 2). Serum ghrelin level was
decreased in the patient group compared to control group,
although this decrease was not significant. No significant differ-
ences detected in fasting serum levels of blood glucose, insulin,
and insulin resistance (assessed by HOMA-IR) (Table 3).
B. Clinical and laboratory characteristics of patient groups before
and after 6 months of LEV treatment:
There were significant decreases in body weight (with a mean
loss of 3.42 kg and ranged between 2 and 4.20 kg) (Fig. 1), BMI
and their Z-scores (p < 0.001), and WC (p = 0.021) after 6 months
of LEV treatment compared to the pretreatment values. In addition,
there were significant increases in WHR (p < 0.001) and height
(p = 0.042) after 6 months of LEV treatment (Table 1).
Table 1
Baseline demographic and clinical data of control group and patients groups at baseline and 6 months after Levetiracetam (LEV) treatment.
Controls (n = 22) Patients (At baseline) (n = 20) Patients (6 months after LEV) (n = 20) P1 P2
Age (years) 8.25 ± 1.29 7.43 ± 1.72 0.085
Sex
Male (n%) 9 (40.9%) 8 (40.0%) 0.951
Female (n%) 13 (59.1%) 12 (60.0%)
Height (cm) 127.35 ± 11.51 122.70 ± 15.04 124.72 ± 14.83 0.213 0.042*
Height-Z 0.36 (1.8 to 2) 0.48 (1.76 to 1.65) 0.53 (1.50 to 1.90) 0.242 0.818
Weight-Z 0.82 (1.67 to 1.69) 0.46 (1.69 to 1.42) 0.69 (1.77 to 1.17) 0.134 <0.001*
BMI (kg/m2) 15.83 ± 3.40 16.41 ± 2.93 13.46 ± 3.25 0.564 <0.001*
BMI-Z 0.94 (1.64 to 1.57) 0.35 (1.74 to 1.36) 0.48 (1.98 to 0.45) 0.352 0.001*
WC (cm) 62.40 ± 5.83 61.9 ± 6.21 60.25 ± 7.20 0.921 0.021*
Waist:Hip ratio 0.89 ± 0.05 0.86 ± 0.05 0.91 ± 0.04 0.183 0.001*
Data are expressed as mean ± SD, as median and range (min–max), or as frequency [number (%)].
WC, Waist circumference; BMI, Body mass index.
P1: test of difference between controls and patients at baseline.
P2: test of difference between patients at baseline and 6 months after LEV treatment.
* p value <0.05 is significant.
Figure 1. Body weight of study groups (control, patients at baseline, and patients
after 6 months of LEV monotherapy). There is non-significant increase (p = 0.742) in
patient body weight at baseline than controls and a significant decrease (p < 0.001)
in body weight in patients after six months of levetiracetam monotherapy in
children with idiopathic focal epilepsy.
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and segmental fat mass (FM) that was only significant in legs FM
(p < 0.041) with significant increase in trunk:leg ratio FM
(p < 0.001). In addition, significant increase in total free fat mass
(FFM) (p = 0.002) and segmental FFM [trunk (p < 0.001) and legs
(p = 0.005)] with significant decrease in trunk:leg ratio FFM
(p < 0.001) were observed after six months of treatment (Table 2).
As regards laboratory investigations, non-significant increase in
ghrelin level (p = 0.191), and non-significant decrease in FBG
(p = 0.642), fasting insulin (p = 0.771), and insulin resistance indexTable 2
Body composition parameters of control group and patients at baseline and 6 months afte
Controls (n = 22) Patients (Baseline) (n = 20)
Fat Mass
Total Body 5.41 ± 3.83 5.08 ± 3.19
Trunk 2.17 ± 1.81 2.17 ± 1.62
Legs 2.38 ± 1.61 2.26 ± 1.21
Arms 0.71 ± 0.45 0.67 ± 0.43
Trunk:Legs ratio 0.89 ± 0.33 0.96 ± 0.47
Free Fat Mass
Total Body 21.31 ± 5.67 18.65 ± 6.78
Trunk 13.4 ± 3.16 12.12 ± 3.55
Legs 6.263 ± 2.0 5.49 ± 2.4
Arms 1.67 ± 0.58 1.55 ± 0.74
Trunk:Legs ratio 2.2 ± 0.3 2.46 ± 0.98
Data expressed as Mean (±SD).
P1: test of difference between controls and patients at baseline.
P2: test of difference between patients at baseline and 6 months after LEV treatment.
* p value <0.05 is significant.(IRI) (p = 0.825) were observed in patients after 6 months of ther-
apy and none of them had insulin resistance (Table 3).
C. Correlations between evaluated parameters among studied
groups:
Among control group, there were significant positive correla-
tions between both fasting serum ghrelin and IR and all the follow-
ing parameters: WC, body FM (total and segmental including
trunk, legs, and arms) and body FFM (total and segmental includ-
ing trunk and legs only). In addition, IRI was negatively correlated
with fasting serum ghrelin [r = 0.716; p < 0.001] (Table 4).
Regarding patient group after 6 months of LEV treatment, no
significant correlation was detected between fasting serum ghrelin
and IRI with anthropometric measurements and body composition
parameters (Table 4).Discussion
The impact of LEV monotherapy on body weight in prepubertal
children has not been defined until now. To the best of our knowl-
edge, this is the first report to estimate the effect of LEV monother-
apy on body weight and body composition in pediatric epilepsy
population.
At baseline evaluation, no significant differences were detected
between patient group (with 1–2 months epilepsy duration) and
control group as regards anthropometric measurements and bodyr LEV treatment.
Patients (6 months after LEV) (n = 20) P1 P2
4.71 ± 2.57 0.762 0.246
2.07 ± 1.31 0.984 0.632
2.06 ± 1.02 0.783 0.041*
0.63 ± 0.37 0.776 0.185
1.07 ± 0.63 0.527 <0.001*
20.19 ± 6.66 0.174 0.002*
12.74 ± 3.61 0.253 <0.001*
5.93 ± 2.45 0.262 0.005*
1.54 ± 0.68 0.561 0.922
2.31 ± 0.65 0.262 <0.001*
Table 3
Laboratory investigations of control and patients groups at baseline and 6 months after LEV treatment.
Controls (n = 22) Patients (At baseline) (n = 20) Patients (6 months After LEV) (n = 20) P1 P2
FBG(mg/dl) 104.25 ± 3.95 104.21 ± 6.87 103.28 ± 7.52 0.981 0.642
Fasting insulin (mIU/ml) 5.85 (3.50–9.20) 5.70 (0.90–9.60) 5.25 (2.90–9.00) 0.623 0.771
HOMA-IR 1.48 (0.83–2.31) 1.42 (0.23–2.44) 1.38 (0.61–2.36) 0.674 0.825
Ghrelin (ng/ml) 2.30 (1.0–4.0) 1.90 (0.70–4.90) 2.95 (0.10–4.80) 0.695 0.191
Data expressed as Mean (±SD) and median (min–max).
FBG, Fasting blood glucose; IR, Insulin resistance.
P1: test of difference between controls and patients at baseline.
P2: test of difference between patients at baseline and 6 months after LEV treatment.
Table 4
Correlation between HOMA-IR and fasting serum ghrelin and different evaluated parameters.
HOMA-IR Fasting serum ghrelin
Control Patients at baseline Patients 6 months after LEV Control Patients at baseline Patients 6 months after LEV
Weight r 0.339 0.044 0.407 0.044 0.073 0.329
P 0.123 0.855 0.075 0.041* 0.759 0.156
BMI r 0.237 0.200 0.274 0.372 0.017 0.171
P 0.288 0.397 0.243 0.088 0.945 0.471
WC r 0.525 0.204 0.214 0.533 0.046 0.340
P 0.012* 0.388 0.365 0.011* 0.846 0.143
Waist:Hip ratio r 0.031 0.188 0.169 0.108 0.019 0.076
P 0.892 0.427 0.445 0.633 0.935 0.750
Body FM r 0.565 0.022 0.192 0.636 0.046 0.232
P 0.006* 0.927 0.418 0.001* 0.846 0.325
Trunk:Legs FM r 0.036 0.200 0.135 0.017 0.327 0.148
P 0.875 0.399 0.571 0.940 0.159 0.533
Fasting insulin r 0.975 0.986 0.988 0.714 0.017 0.440
P <0.001* <0.001* <0.001* <0.001* 0.943 0.052
Fasting gherlin r 0.716 0.034 0.420
P <0.001* 0.886 0.066
r, Spearmann correlation coefficient; P, probability.
WC, waist circumference; BMI, body mass index; FM, fat mass; IR, insulin resistance.
* p value <0.05 is significant.
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lepsy per se on previously evaluated parameters. In contrast to
our results, Daniels et al. found that obesity is a common comor-
bidity in a cohort of children and adolescents (2–18 years) with
newly diagnosed untreated epilepsy who were evaluated within
10 days of referral.25 These contrary results are likely due to the
smaller sample size and younger age of patients in the present
study.
On the other hand, anthropometric parameters of the patient
group after six months of LEV treatment showed a significant
decrease in body weight, BMI, and their Z-scores compared to pre-
treatment values. However, the observed significant weight loss
does not affect the patients growth as significant increase in
patients’ height were observed after 6 months of LEV treatment
compared with pretreatment level. The ages of our study popula-
tions (6–10 y) is the age range in which height and weight gain
are expected. This continued statural growth provides evidence
that LEV treatment with an average dose of 30 mg/kg/day did not
adversely affect linear bone growth.
The significant weight loss that observed after 6 months of LEV
treatment can be partially explained by appetite loss that reported
after initiation of treatment in some patients (12 out of 20 epileptic
children). Similarly, anorexia has been listed as a common side
effect of LEV treatment and was reported in 1–18% of patients.26,27
Reviewing the literature showed that data regarding the impact
of LEV on body weight were conducted mainly on adult population
and their results have been conflicting. Similar to our results, Cra-
mer and her colleagues found that weight loss was a treatment
adverse event in a group of 97 elderly patients treated with
LEV.15 In addition, intense weight loss (with a mean of 26.75 kg)has been reported in four patients under LEV co-therapy in a dose
ranging between 2000 and 3000 mg/day.16 As well, Gelisse et al.
found that LEV accompanied with marked weight loss at lower
doses of 500–2000 mg/day.17 Contrary to our findings, LEV is
considered a ‘‘weight-neutral” AED as documented by Gidal and
his colleagues,13 and Briggs and French, as well.14 Alternatively,
Pickrell and his colleagues noticed a significant weight gain associ-
ated with LEV and valproic.28
These controversial results reported by previous studies may be
related to different factors including; inclusion of different age
groups (from adolescents to elderly patients) with different growth
and developmental stages, inclusion of patients with long history
of AEDs intake with different drug dosage and duration of treat-
ment, and a possibility of other comorbidities that affect body
weight.
It is well known that during mid-childhood, around the age of
8 years, a preadolescent ‘‘fat wave” or ‘‘adiposity rebound” occur,29
after which, the total body fat continues to increase throughout
puberty at an estimate rate about 1.4 kg/year in girls and
0.6 kg/year in boys. Adolescent girls add more fat on their arms,
legs, and trunk, while the arm and leg fat of adolescent boys
decreases.30 In contrast, LEV-associated weight loss was observed
in our patients after 6 months of LEV therapy compared to pre-
treatment parameter and was related mainly to reduction in body
fat stores as evidenced by a decrease in total and segmental fat
mass. This decrease in fat mass was only significant in legs with
a significant increase in trunk:leg fat mass ratio. The observed
changes in fat distribution cannot be explained by the effect of
sex steroid as all patients included in the present study were
pre-pubertal. Fortunately, neither the increase in trunk:leg fat
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with insulin resistance, which has significant impact on body fat
distribution.
Contrary to body fat mass, the FFM (total body, trunk, and legs)
increased significantly after six months of LEV therapy. This finding
in part clarify that the growth of patients (as regards muscles) were
not affected by LEV treatment.
In addition, lean mass is influenced by physical exercise or
sports activity whereas constant physical activity increases the
proportion of lean body mass and reduces the fat compartment,
even without changes in body weight.31 Children with epilepsy
tend to be less physically active before initiation of AEDs or control
of seizures due to the fear of injuries and the fear that seizures may
be provoked by exercise or blows to the head. However, once the
patients’ seizures are well controlled, they were allowed to partic-
ipate in group and total sports activities with some limitations.32
To evaluate possible mechanisms of weight changes associated
with LEV monotherapy, we studied serum ghrelin, fasting insulin,
and fasting blood glucose levels at baseline and after six months
after of LEV treatment. Ghrelin is a peptide-like hormone that is
produced in the gastrointestinal system and contributes to positive
energy balance. We observed that, ghrelin level tends to decrease
in the patient group compared with a matched control at baseline.
This finding was partially in accordance with Aydin and his
colleagues who reported that, serum and saliva ghrelin levels were
significantly (2-fold) lower in epileptic patients before treatment
than in controls.33 These results can be explained by the associa-
tion between ghrelin and etiopathognesis of epilepsy, that has
been confirmed in human and animal studies, despite the contro-
versial results.34 In addition, the decreased ghrelin level before
starting treatment might be related to the increased uptake of
ghrelin by brain under effect of pathophysiological events to mod-
ify epileptic discharges.35 Bhatt and his colleagues, and also Hum
and his colleagues explained that decreased ghrelin level in
untreated rats was due to the detected high serum leptin levels
after seizures,36 which might impede ghrelin secretion directly.37
On the other hand, the levels of ghrelin increased non-signifi-
cantly after six months of LEV treatment that might be due to feed-
back mechanism induced by the observed weight loss and reported
anorexia or by direct effect of LEV on ghrelin secretion. This result
is in accordance with Berilgen and his colleagues,38 and Aydin and
his colleagues who found that, serum and saliva ghrelin levels were
increased in epileptic patients under treatment with AEDS.34
The previous studies were conducted on patients who were
already on AEDs, so it is difficult to delineate whether increased
ghrelin was due to the seizure or due to the effect of AEDs.38 How-
ever, in the present study ghrelin level was decreased prior to start
of treatment and increased after six months of LEV monotherapy
which highlights the possible modulation of ghrelin secretion by
LEV treatment. In addition, all enrolled children were prepubertal
and achieved complete control of the seizure on LEV monotherapy
in order to exclude possible modulation of ghrelin secretion by
pubertal stage, age, and seizure activity.39
Finally, a non-significant decrease of FBG, and fasting insulin
levels was found in the patient group after six months of LEV treat-
ment which was in accordance to Heppner and Tong who found
that increased ghrelin levels impede the insulin secretion stimu-
lated by glucose.40 None of included epileptic children in the pre-
sent study exhibited IR assessed by HOMA method.Conclusion
LEV monotherapy in prepubertal children associated with a sig-
nificant weight loss that is related mainly to decrease in body fat
particularly from legs. However, statural growth was not affectedas evident by a significant increase in patients’ height, total and
segmental FFM after 6 months of LEV treatment compared with
pretreatment level. Serum level of ghrelin tends to increase after
6 months treatment compared to pretreatment levels. This
increased ghrelin level might be due to feedback mechanism
induced by weight loss and anorexia or by direct effect of LEV on
ghrelin secretion.
Study limitations
The present study was limited by the relatively small size of the
cohort and also the lack of detailed dietary intake and physical
activity assessment.
Recommendations
A future long-term large scale study is needed for more delin-
eation of the effect of LEV monotherapy on body weight and its
exact mechanism of weight affection with emphasis on the role
of ghrelin as a contributing factor.Funding
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